Trials / Completed
CompletedNCT04881747
A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants
Bioequivalence of Lasmiditan Oral Disintegrating Tablet Compared to Current Immediate-Release Tablet Formulation to Support Treatment of Migraine
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to compare the amount of lasmiditan that gets into the blood stream and how long it takes the body to get rid of it, when given as a oral-disintegrating (OD) tablet compared to immediate-release (IR) tablet formulation. The information about any adverse effects experienced will be collected and the tolerability of lasmiditan when administered as OD tablet will also be evaluated. Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be about 5 weeks, including screening.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lasmiditan | Administered orally. |
Timeline
- Start date
- 2021-05-14
- Primary completion
- 2021-07-24
- Completion
- 2021-07-24
- First posted
- 2021-05-11
- Last updated
- 2023-03-23
- Results posted
- 2023-03-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04881747. Inclusion in this directory is not an endorsement.